This summary was created by AI, based on 6 opinions in the last 12 months.
Viatris (VTRS-Q) has faced challenges recently, including a drop in stock price following weak earnings and an FDA investigation impacting its EBITDA. Despite these hurdles, several experts highlight the company's strong free cash flow and the upcoming share buyback, viewing it as a solid use of capital. The stock is considered cheap with a low price-to-earnings (PE) ratio of around 4-5x and offers a dividend yield exceeding 4%. Although some investors express concern over management's focus on acquisitions rather than stock buybacks or debt paydown, many believe the company is finally on a path to better performance. Overall, there is cautious optimism surrounding the future outlook as the company prepares for an important earnings report amidst ongoing restructuring efforts.
It is the cheapest stock in their portfolio at 4X earnings, a pharma company formed by a joint venture. Its investment grade bond issues are in rock solid shape. It sold a division for $2 billion and will use the cash for a couple of acquisitions in eye wear and to buy back stock. There are potential sales of other smaller divisions so there could be more buybacks plus paying down debt. The dividend yield is 4.1%. Has a low price due to a couple of disappointing quarters but numbers have been solid since. Also revenues have been flat-lining.
Buy 4 Hold 10 Sell 0
Viatris is a American stock, trading under the symbol VTRS-Q on the NASDAQ (VTRS). It is usually referred to as NASDAQ:VTRS or VTRS-Q
In the last year, 6 stock analysts published opinions about VTRS-Q. 3 analysts recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Viatris.
Viatris was recommended as a Top Pick by on . Read the latest stock experts ratings for Viatris.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
6 stock analysts on Stockchase covered Viatris In the last year. It is a trending stock that is worth watching.
On 2025-04-03, Viatris (VTRS-Q) stock closed at a price of $8.16.
Proof that not every stock he buys goes up ;) He's held for years. Recent earnings were weak, and stock fell ~15%. Generating significant free cashflow, which now will be used to buy back shares incredibly cheaply. It's the best use of capital at this time. FDA investigation in one of their plants, costing about $300-400M in EBITDA. Yield is 4+%.